Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data
- PMID: 21968047
- PMCID: PMC3233295
- DOI: 10.1634/theoncologist.2011-0229
Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data
Abstract
Background: Treatment of multiple myeloma has changed significantly over the past several years with clinical trials reporting superior survival results using newer agents. Previous work has shown that the survival rate has improved for younger, but not older, patients with myeloma. Here, we update survival estimates for patients with myeloma in the early 21st century to determine whether continued improvement can be seen on a population level and whether or not it now extends to older patients.
Methods: Using period analysis to examine data from the Surveillance, Epidemiology, and End Results database, we estimate changes in the 5- and 10-year relative survival rates (RSRs) from 1998-2002 to 2003-2007.
Results: The 5- and 10-year RSRs have improved for patients with myeloma overall, from 32.8% and 15% in 1998-2002 to 40.3% and 20.8%, respectively, in 2003-2007. The greatest improvements were observed for patients aged 15-44 years, with 5- and 10-year RSRs reaching >70% and ~50%, respectively, but improvements were also seen for patients aged >70 years.
Conclusion: Overall, survival continues to improve for patients with myeloma, including older patients, suggesting that newer treatment options continue to make a population-wide impact.
Conflict of interest statement
Similar articles
-
Disease-specific survival for patients with multiple myeloma: significant improvements over time in all age groups.Leuk Lymphoma. 2014 Dec;55(12):2850-7. doi: 10.3109/10428194.2014.897700. Epub 2014 May 9. Leuk Lymphoma. 2014. PMID: 24588734
-
Plasma Cell Myeloma - 20-Year Comparative Survival and Mortality of Three Plasma Cell Myeloma ICD-O-3 Oncologic Phenotypes by Age, Sex, Race, Stage, Cohort Entry Time-Period and Disease Duration: A Systematic Review of 111,041 Cases for Diagnosis Years 1973-2014: (SEER*Stat 8.3.4).J Insur Med. 2018;47(4):203-211. doi: 10.17849/insm-47-04-1-9.1. Epub 2019 Jan 22. J Insur Med. 2018. PMID: 30668210
-
Trends in survival of multiple myeloma patients in Germany and the United States in the first decade of the 21st century.Br J Haematol. 2015 Oct;171(2):189-196. doi: 10.1111/bjh.13537. Epub 2015 Jun 30. Br J Haematol. 2015. PMID: 26123295
-
Leukemias, myeloma, and other lymphoreticular neoplasms.Cancer. 1995 Jan 1;75(1 Suppl):381-94. doi: 10.1002/1097-0142(19950101)75:1+<381::aid-cncr2820751320>3.0.co;2-b. Cancer. 1995. PMID: 8001009
-
The epidemiology of multiple myeloma.Hematol Oncol Clin North Am. 1992 Apr;6(2):225-47. Hematol Oncol Clin North Am. 1992. PMID: 1582971 Review.
Cited by
-
Diagnostic and therapeutic approaches to multiple myeloma patients: 'Real-world' data from representative multicentre treatment surveys in Germany between 2008 and 2011.Oncol Lett. 2016 Dec;12(6):5043-5051. doi: 10.3892/ol.2016.5375. Epub 2016 Nov 10. Oncol Lett. 2016. PMID: 28105211 Free PMC article.
-
Cost-Effectiveness of Autologous Hematopoietic Stem Cell Transplantation for Elderly Patients with Multiple Myeloma using the Surveillance, Epidemiology, and End Results-Medicare Database.Biol Blood Marrow Transplant. 2015 Oct;21(10):1823-9. doi: 10.1016/j.bbmt.2015.05.013. Epub 2015 May 30. Biol Blood Marrow Transplant. 2015. PMID: 26033281 Free PMC article.
-
Harnessing Nanotechnology: Emerging Strategies for Multiple Myeloma Therapy.Biomolecules. 2024 Jan 9;14(1):83. doi: 10.3390/biom14010083. Biomolecules. 2024. PMID: 38254683 Free PMC article. Review.
-
Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years.Bone Marrow Transplant. 2015 Feb;50(2):209-15. doi: 10.1038/bmt.2014.255. Epub 2014 Nov 10. Bone Marrow Transplant. 2015. PMID: 25387088 Clinical Trial.
-
Bortezomib for the treatment of multiple myeloma.Cochrane Database Syst Rev. 2016 Apr 20;4(4):CD010816. doi: 10.1002/14651858.CD010816.pub2. Cochrane Database Syst Rev. 2016. PMID: 27096326 Free PMC article.
References
-
- Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300. - PubMed
-
- Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood. 2008;111:2521–2526. - PubMed
-
- Wijermans P, Schaafsma M, Termorshuizen F, et al. Phase III study of the value of thalidomide added to melphelan plus prednisone in elderly patients with newly diagnosed multiple myeloma: The HOVON 49 Study. J Clin Oncol. 2010;28:3160–3166. - PubMed
-
- San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359:906–917. - PubMed
-
- DCCPS, Surveillance Research Program, Cancer Statistics Branch. Bethesda. MD: National Cancer Institute; 2011. [accessed September 28, 2011]. Surveillance, Epidemiology, and End Results (SEER) Program Limited Use Data (1973–2008). Released April, 2011 based on November 2010 submission. Available at www.seer.cancer.gov.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous